Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 3Stomach Neoplasms 1Neoplasms 1NSCLC 1HER2-positive Colorectal Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Endometrial Neoplasms 1Colonic Neoplasms 1Advanced Malignancies 1Advanced Colorectal Cancer 1

Interventions

Paclitaxel 25Doxorubicin 15Carboplatin 14pembrolizumab 10Cisplatin 8Radiotherapy 6Docetaxel 5Chemotherapy, Adjuvant 5Taxes 4Filgrastim 4Brachytherapy 4lenvatinib 3Observation 3trastuzumab deruxtecan 2selinexor 2olaparib 2durvalumab 2Tamoxifen 2Specimen Handling 2Ifosfamide 2Drug Therapy 2sintilimab 1sacituzumab govitecan 1pertuzumab 1nanocis 1liposomal doxorubicin 1ixabepilone 1gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1dostarlimab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Endometrial Neoplasms × HMPL-013 × Clear all
NCT06584032 2025-01-07

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Hutchmed

Phase 3 Recruiting
412 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡